Introduction
Sigma (σ) receptors are a distinct non-opioid, class of receptors that are located in the central nervous system as well as in a 20 variety of peripheral tissues and organs.
1 These receptors are unique proteins located in plasma, mitochondrial and endoplasmic reticulum membranes of tissue derived from brain, kidney, liver, immune, endocrine and reproductive organs. 2 Based on drug-binding profiles and specific pharmacological 25 characteristics of σ-receptor ligands, two distinct receptor subtypes denoted sigma-1 (σ 1 ) and sigma-2 (σ 2 ) have been identified with molecular weights of ~25 kDa (σ 1 ), and ~21.5 kDa (σ 2 ). 3 The σ 1 -receptor has recently been identified as a unique ligand-regulated molecular chaperone in the endoplasmic 30 reticulum of cells involved in the regulation and modulation of voltage-regulated and ligand-gated ion channels, including Ca The findings that neuroactive steroids bind with moderate affinity to σ 1 sites, suggest that σ 1 receptors may modulate the activity of 35 GABA and NMDA receptors in the CNS. 5 These observations have rekindled interest in assessing their potential role in inhibiting or potentiating ion channels with implications in many neurological diseases, amnesia, pain, depression, schizophrenia, and neuroprotection. The discovery of the presence of σ 1 and σ 2 receptors in many human and rodent tumours has opened new possibilities in the area of cancer research, particularly the involvement of σ 2 receptors. 7 In an initial screening of human brain tumours, σ receptors were detected in 15 of 16 tumors examined. Strong 45 receptor expression was observed in a brain metastasis from a lung adenocarcinoma and in a human neuroblastoma passaged in nude mice 8 , whereas a 2-to-5-fold overexpressed in renal and colon carcinomas 9 was also found. Observations that a higher number of binding sites was observed for the non-subtype- cell lines, suggested that the σ2 receptor is more abundant than the σ 1 subtype. However, immunocytochemical staining did 55 detect σ 1 receptors in the majority of human primary breast carcinomas, particularly in tumours with a positive progesterone receptor status.
10
Over-expression of σ 2 receptors has been observed in primary colon cancers, renal carcinomas and sarcomas 9 and pancreatic 60 cancers. 11 Recently it was shown that the σ 2 receptor density in proliferative breast cancer cells is about tenfold higher than in quiescent breast cancer cells 12 and that σ 2 receptor expression is up-regulated during the transition from quiescence to proliferation and down-regulated during the transition from receptor ligands may have a potential role in the treatment of tumours 17 while specific radiolabelled σ 2 receptor ligands can be 5 used to image tumour cell proliferation in vivo using positron emission tomography (PET) or single-photon emission computed tomography (SPECT).
18
The σ 2 receptor has not been cloned and its structure has not been determined. However, recently, the σ 2 receptor, was 10 identified as the progesterone receptor membrane component 1 (Pgrmc1) using photo-affinity studies and a σ 2 ligand containing both a photoactive azide moiety and a fluorescein isothiocyanate group for protein visualisation. 19 This protein was also found to be up-regulated in multiple types of cancer and shown that 15 Pgrmc1 is required for tumour cell proliferation, motility and tumour formation in vivo. Furthermore, small molecule inhibitors of Pgrmc1, such as AG-205 (5, Figure 1 ), suppressed the growth of lung, breast and cervical cancer cell lines. 20 A number of structurally-diverse compounds have been shown 20 to possess high affinity to σ receptors. 21 However, most of these compounds were shown to bind selectively to the σ 1 receptor or have similar affinities to both σ 1 and σ 2 receptors. Some early σ 2 selective ligands reported in the literature include the benzomorphan-7-one analogue CB-64D (3) 22 , the 3-(ω-25 aminoalkyl)-1H-indole analogue Lu 28-179 (siramesine, 4) 23 , ibogaine 24 , and the tropane analogue WC-59 (6). 25 These, and later σ 2 ligands, have been recently comprehensively reviewed. 26 SAR studies based on a series of conformationally-flexible benzamide analogues, initially developed as D 3 -selective 30 ligands, 27d,e,f produced a class of compounds having a high affinity for σ 2 receptors and excellent σ 2 :σ 1 selectivity ratios. 27 A key development in this series of compounds was the presence of a 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline ring. This not only resulted in compounds having a high affinity and excellent 35 selectivity for σ 2 versus σ 1 receptors, but dramatically reduced their affinity for dopamine receptors. Further modifications, including the incorporation of fluorescent and radiolabelled probes produced molecules, e.g. WC-59 (6) with significant σ 2 affinity and selectivity. 28 These σ 2 selective ligands have 40 subsequently been used to directly identify, locate and quantify this protein using a variety of receptor-binding and molecular imaging techniques.
29
Molecules based on the conformationally-flexible benzamide 1 have proven to be an important source of σ 2 -selective 45 compounds. Preliminary work has shown that having a conformationally flexible spacer unit of four carbon atoms was beneficial for σ 2 binding affinity and selectivity. 27a However, limited work was undertaken on the effects of substitutions on the carboxylic acid and no work had been performed to observe what 50 effect restricting conformational freedom has on σ 2 receptor activity in this class. Further, little work has been conducted on varying the substitution pattern of the methoxy groups on the tetrahydroisoquinoline ring, although, it has been shown that either opening the tetrahydroisoquinyl ring or replacing the 55 methoxy groups with methylene-, ethylene-and propylenedioxy rings decrease the σ 2 activity. 27b, 30 Despite these results, there remains considerable scope for further modifications to this structure for the preparation of radiolabeled probes to image this receptor in vitro and in vivo. In this study, the effect of 60 modulating the conformational freedom of the spacer, varying the carboxylic acid substitution on the amide and modifying the methoxy substitution on the tetrahydroisoquinolyl ring was 
Scheme 1 Reagents: a) di-tert-butyldicarbonate, CH2Cl2, b) PPh3, I2, imidazole, c) 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride, TBAI, K2CO3, DMF, d) CH2Cl2/TFA (2:1), e) EDC, HOBt, DMF, R-COOH, f) EDC, HOBt, DMF, 5-substituted-benzofuran-2-carboxylic acids.
investigated with the purpose of expanding the scope of analogues synthesised and evaluated to produce a candidate that 5 was suitable for radiolabelling with SPECT and PET isotopes.
Results and discussion

Chemistry
Using the tetrahydroisoquinoline benzamide 1 as our lead compound, we synthesised a series of analogues and tested them 10 as selective σ 2 ligands. Therefore, the substituted piperidines 7-9 were Boc N-protected (10-12), followed by the incorporation of a leaving group using standard chemistry (Scheme 1). The addition of the 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline unit under S N 2 reaction conditions (16) (17) (18) two methylene units (37) resulted in slight improvements in activity but at a significant expense to selectivity. The lead compound 1 had a flexible four carbon linker and a bromodimethoxyphenyl ring at the terminus. The incorporation of the restricted linker and the methylpiperidine core (22) decreased 15 activity and selectivity for the σ 2 receptor (σ 2 = 367 nM, σ 1 /σ 2 = 5.9) compared to the lead 1. Given the best terminal aromatic group was a bromobenzofuran, the corresponding flexible linker versions were synthesised (54-59). Surprisingly the C5-iodosusbtituted benzofuran 59 produced the best outcome (σ 2 = 20 0.88 nM, σ 1 /σ 2 = 886) with an order of magnitude better σ 2 activity and the best selectivity over σ 1 that we have seen.
Our final series of analogues investigated examined the removal of one of the tetrahydroisoquinoline methoxy substitutents and the size of the flexible linker (60-63). While 25 significant activity was noted for the monomethoxy derivative 61, the selectivity was notably reduced.
Therefore, the optimal ligand for σ 2 activity and selectivity was the iodobenzofuran 59 containing a benzofuran carboxamide moiety with a halogen substitution at C5 and a 6,7-30 dimethoxytetrahydroisoquinoline separated by a six carbon flexible spacer. This possessed a σ 2 activity of 0.88 nM with a selectivity index of 886. On the other hand, the best ligand for σ 1 activity was 61 with a value of 76 nM and a σ 2 value of 4.4 nM. This relatively poor activity for σ 1 was still significantly better 35 than most other derivatives and also still possessed better σ 2 activity. Therefore, the σ 2 activity for this series, along with the consistently good selectivity values can be seen as significant and consistent and validates pursuing this extended SAR study. Figure 2 shows a summary of the structure-activity results that have emerged from this study. Of the great variety of terminal aromatic moieties investigated, the benzofuran was the most potent, particularly with the presence of a C5-iodo substituent.
45
The central linker is best if flexible and is optimal at six methylenes. Although the dimethoxy substituted tetrahydroisoquinoline exhibits good in vitro activity with just one methoxy substituent, it does at the expense of selectivity and appears to be optimal with 2 methoxy substituents present. Table 3 σ1 and σ2 binding affinities (Ki) for benzamides. Carboxamide Region i) Benzofuran with a C5-Br or -I is optimal. Indole or benzothiophene showasimilar σ 2 activity -indole is more selective. ii) A C3 or C6 carboxylate linkage decreases σ 2 activity. iii) Replacing heterocycles with aromatics (e.g Ph, naphthyl) decreases σ 2 activity and selectivity.
Hydrophobic Spacer
The flexible 6xC spacer optimal.
Decreasing the spacer length or rigidification decreases σ 2 activity and selectivity.
Isoquinoline Linker
The 6,7-dimethoxy is optimal with variation in substitution decreasing σ 2 activity and selectivity. 
Conclusion
10
A series of tetrahydroisoquinolyl benzamides were synthesised and tested for their binding affinities to both σ 1 and σ 2 . We have shown that this class of derivatives can be highly potent and selective for the σ 2 receptor, with the piperidine based core favoured in most cases. The halogenated benzofuran derivatives 15 34 (K i σ 1/ σ 2 = 292) and 35 (K i σ 1/ σ 2 = 62.0) displaying good affinity and selectivity and increasing the conformational freedom produced more σ 2 active derivatives. However, this also decreased σ 2 selectivity in all cases except for that of 59 (k i σ 1/ σ 2 = 886). Removal of the methoxy groups from the isoquinoline 20 ring did not produce a more selective or high affinity ligand than that seen for compound 59, and these results corroborate the need to have a flexible linker with a 6,7-dimethoxy isoquinyl ring substitution for optimum σ 2 binding affinity. In addition, structural features were identified that result in extremely poor 25 affinity and selectivity for both the σ 1 and σ 2 receptor subtypes. Therefore, the new information from our study offers a useful guide for designing σ 2 specific compounds and promising new lead compounds 34 and 59 were produced, that show highly active σ 2 activity with significant selectivity, and have the 30 potential to be utilised in future SPECT radiochemistry studies.
Experimental
Chemistry -general considerations
All reagents purchased were used without further purification. 50 the log P value using literature procedures. 31 Samples, dissolved in methanol, were analyzed using a Waters, Xterra C18 column (5 μm, 4.6 mm × 150 mm) with a mobile phase consisting of methanol/phosphate buffer (0.1 M, pH 7.5) and a flow rate of 1 mL/min. The log P of a studied compound was estimated by a 55 comparison of its retention time to that of compounds of known log P value.
Preparation of Compounds 16-18
To a solution of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (1.0 eq), K 2 CO 3 (4 eq) and TBAI (0.1 eq) in DMF 60 (20 mL) was added the appropriate piperidine 13, 14, or 15 (1.0 eq). The solution was allowed to stir at rt for 3 days. The solution was diluted with EtOAc (100 mL) and extracted with H 2 O (3 x 20 mL), sat. NaHCO 3 (25 mL), brine (25 mL) and H 2 O (20 mL). The organic layers were combined, dried (Na 2 SO 4 ) and the (s, 2H), 3.83 (s, 6H), 4.08-4.10 (bs, 2H), 6.52 (s, 1H), 6.59 (s, 1H). 13 (1 M, 200 mL) followed by aq. KOH (0.1 M, 50 mL) and extracted with CH 2 Cl 2 (3 x 100 mL). The organic layers were combined, dried (Na 2 SO 4 ) and the solvent removed to yield 19, 20 or 21 which were used without further purification. 4-(2-(3,4-Dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)ethyl)piperidin-1-yl)(5-iodobenzofuran-2-yl) 55.6, 55.9, 56.0, 87.1, 109.6, 110.3, 111.5, 113.9, 126.2,  126.6, 129.8, 131.0, 134.9, 147.3, 147.7, 150.2, 153.9, 159 85 To a solution of the appropriate nitrile derivative (1 eq) in DMF (20 mL) was added either 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (1 eq), or 6-methoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride 34 (1 eq), or 7-methoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride (1 eq), 90 followed by K 2 CO 3 (4 eq), TBAI (0.1 eq) and KI (0.01 eq) and the solution stirred for 16 h. The reaction mixture was then diluted with EtOAc (100 mL) and extracted with H 2 O (3 x 20 mL), sat. NaHCO 3 (25 mL), brine (25 mL) and H 2 O (20 mL). The organic layers were combined, dried (Na 2 SO 4 ) and the 95 organic solvent removed. The residue was purified column chromatography (EtOAc:MeOH, 9:1). Clear oil, yield 83%; 1 H NMR (CDCl 3 ) δ 1.73-1.77 (m, 4H), 2.39 (t, 2H, J = 6.6 Hz), 2.53 (t, 2H, J = 6.6 Hz), 2.69 (t, 2H, J = 6.0 Hz), 2.81 (t, 2H, J = 5.8 Hz), 3.54 (s, 2H), 3.83 (s, 3H), 3.84 (s, 3H), 6.52 (s, 1H), 6.59 (s, 1H). 13 
5-Bromobenzofuran-2-yl)(4-(2-(3,4-dihydro-6,7-
Preparation of compounds 40-46
4-(3,4-Dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butanenitrile
Preparation of compounds 47-53
To a suspension of LiAlH 4 (3 eq) in dry THF (50 mL) was added 50 the appropriate nitrile (1 eq) in dry THF (25 mL) dropwise under a stream of N 2 . The resulting mixture was heated at reflux for 18 h under N 2 . To the cooled solution at 0 o C was added iced H 2 O (5 mL) and 10% NaOH (15 mL). The solution was warmed to rt and allowed to stir for 15 min. The resulting suspension was 55 filtered through celite and the filter cake washed with EtOAc (50 mL). The organic layer was dried (Na 2 SO 4 ) and solvent removed to give 46-52 which were used without further purification.
4-(3,4-Dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butan-1- -N-(4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butyl)-1-benzofuran-2 
5-Bromo
